<DOC>
	<DOC>NCT00680745</DOC>
	<brief_summary>This study is being carried out to see if dapagliflozin in addition to glimepiride (sulphonylurea) is effective and safe in treating patients with type 2 diabetes when compared to glimepiride alone.</brief_summary>
	<brief_title>Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10% Type 1 Diabetes Hepatic (liver) impairment Renal (kidney) failure or dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>sulphonylurea</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>